Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OPTIMIST trial of minimally invasive surfactant therapy in preterm infants on CPAP
NL-OMON44166Active, not recruiting
- Sponsor
- Menzies Institute for Medical Research
- Start
- Jul 2016
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Randomised, single-blind trial of Poractant alfa in respiratory distress syndrome (RDS) (2 arms), sponsored by Menzies Institute for Medical Research. Primary endpoint: Composite of death or physiological bronchopulmonary dysplasia. Started Jul 2016; status: active, not recruiting.
02
Drugs
Poractant alfa
03
Conditions
respiratory distress syndrome (RDS)
Beyond the preview
Go deeper on NL-OMON44166.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON44166.